Engineered immune cells take on ovarian cancer in early trial
NCT ID NCT04670068
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 31 times
Summary
This early-phase study tests a new treatment for ovarian cancer that has come back after previous therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to find the safest dose and check for side effects in up to 21 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.